Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.59
BCR's Cash-to-Debt is ranked lower than
67% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. BCR: 0.59 )
Ranked among companies with meaningful Cash-to-Debt only.
BCR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.59 Max: 4.9
Current: 0.59
0.06
4.9
Equity-to-Asset 0.35
BCR's Equity-to-Asset is ranked lower than
83% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. BCR: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
BCR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.54 Max: 0.77
Current: 0.35
0.28
0.77
Debt-to-Equity 0.89
BCR's Debt-to-Equity is ranked lower than
84% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.31 vs. BCR: 0.89 )
Ranked among companies with meaningful Debt-to-Equity only.
BCR' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07  Med: 0.43 Max: 1.14
Current: 0.89
0.07
1.14
Interest Coverage 16.48
BCR's Interest Coverage is ranked lower than
62% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.83 vs. BCR: 16.48 )
Ranked among companies with meaningful Interest Coverage only.
BCR' s Interest Coverage Range Over the Past 10 Years
Min: 15.05  Med: 23.74 Max: 60.49
Current: 16.48
15.05
60.49
Piotroski F-Score: 8
Altman Z-Score: 5.23
Beneish M-Score: -2.39
WACC vs ROIC
4.65%
33.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 25.83
BCR's Operating Margin % is ranked higher than
90% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. BCR: 25.83 )
Ranked among companies with meaningful Operating Margin % only.
BCR' s Operating Margin % Range Over the Past 10 Years
Min: 18.91  Med: 25.4 Max: 39.79
Current: 25.83
18.91
39.79
Net Margin % 14.99
BCR's Net Margin % is ranked higher than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. BCR: 14.99 )
Ranked among companies with meaningful Net Margin % only.
BCR' s Net Margin % Range Over the Past 10 Years
Min: 3.96  Med: 17.46 Max: 22.62
Current: 14.99
3.96
22.62
ROE % 33.39
BCR's ROE % is ranked higher than
96% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. BCR: 33.39 )
Ranked among companies with meaningful ROE % only.
BCR' s ROE % Range Over the Past 10 Years
Min: 8.19  Med: 22.49 Max: 33.78
Current: 33.39
8.19
33.78
ROA % 10.84
BCR's ROA % is ranked higher than
82% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. BCR: 10.84 )
Ranked among companies with meaningful ROA % only.
BCR' s ROA % Range Over the Past 10 Years
Min: 2.73  Med: 14.07 Max: 17.1
Current: 10.84
2.73
17.1
ROC (Joel Greenblatt) % 82.58
BCR's ROC (Joel Greenblatt) % is ranked higher than
91% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. BCR: 82.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BCR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.37  Med: 81.73 Max: 148.85
Current: 82.58
53.37
148.85
3-Year Revenue Growth Rate 9.30
BCR's 3-Year Revenue Growth Rate is ranked higher than
69% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. BCR: 9.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BCR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.7  Med: 9.1 Max: 13.9
Current: 9.3
-0.7
13.9
3-Year EBITDA Growth Rate -10.70
BCR's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BCR: -10.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BCR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.9  Med: 8.6 Max: 41.1
Current: -10.7
-18.9
41.1
3-Year EPS without NRI Growth Rate -5.70
BCR's 3-Year EPS without NRI Growth Rate is ranked lower than
60% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. BCR: -5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BCR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34  Med: 10.1 Max: 43.4
Current: -5.7
-34
43.4
GuruFocus has detected 4 Warning Signs with C.R. Bard Inc $BCR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BCR's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

BCR Guru Trades in Q3 2016

Jeremy Grantham 98,050 sh (New)
Steven Cohen 229,200 sh (New)
Paul Tudor Jones 126,800 sh (+11427.27%)
Louis Moore Bacon 2,426 sh (+168.36%)
Tom Gayner Sold Out
Pioneer Investments 271,837 sh (-5.96%)
Donald Yacktman 738,964 sh (-8.35%)
Yacktman Fund 550,000 sh (-15.38%)
Jim Simons 797,200 sh (-25.02%)
Joel Greenblatt 3,760 sh (-32.64%)
Ray Dalio 6,915 sh (-66.78%)
» More
Q4 2016

BCR Guru Trades in Q4 2016

George Soros 900 sh (New)
Joel Greenblatt 50,845 sh (+1252.26%)
Steven Cohen 382,200 sh (+66.75%)
Yacktman Fund 550,000 sh (unchged)
Ray Dalio Sold Out
Donald Yacktman 723,901 sh (-2.04%)
Jeremy Grantham 95,867 sh (-2.23%)
Jim Simons 509,400 sh (-36.10%)
Paul Tudor Jones 75,000 sh (-40.85%)
Pioneer Investments 31,481 sh (-88.42%)
» More
Q1 2017

BCR Guru Trades in Q1 2017

Caxton Associates 2,600 sh (New)
Ray Dalio 3,964 sh (New)
Jim Simons 956,700 sh (+87.81%)
Pioneer Investments 31,640 sh (+0.51%)
George Soros Sold Out
Louis Moore Bacon Sold Out
Steven Cohen 316,353 sh (-17.23%)
Donald Yacktman 496,394 sh (-31.43%)
Yacktman Fund 350,000 sh (-36.36%)
Joel Greenblatt 12,431 sh (-75.55%)
Jeremy Grantham 5,927 sh (-93.82%)
Paul Tudor Jones 1,853 sh (-97.53%)
» More
Q2 2017

BCR Guru Trades in Q2 2017

Mario Gabelli 31,592 sh (New)
Leucadia National 41,708 sh (New)
George Soros 45,772 sh (New)
Lee Ainslie 7,620 sh (New)
John Paulson 42,122 sh (New)
Paul Tudor Jones 151,871 sh (+8095.95%)
Jeremy Grantham 370,000 sh (+6142.62%)
Jim Simons 1,295,600 sh (+35.42%)
Yacktman Fund Sold Out
Pioneer Investments Sold Out
Donald Yacktman Sold Out
Ray Dalio Sold Out
Steven Cohen Sold Out
Joel Greenblatt 10,081 sh (-18.90%)
Caxton Associates 1,500 sh (-42.31%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2017-06-30 New Buy0.32%$248.4 - $316.12 $ 318.638%45,772
John Paulson 2017-06-30 New Buy0.18%$248.4 - $316.12 $ 318.638%42,122
Leucadia National 2017-06-30 New Buy1.14%$248.4 - $316.12 $ 318.638%41,708
Mario Gabelli 2017-06-30 New Buy0.06%$248.4 - $316.12 $ 318.638%31,592
Joel Greenblatt 2017-06-30 Reduce -18.90%0.01%$248.4 - $316.12 $ 318.638%10,081
Donald Yacktman 2017-06-30 Sold Out 1.15%$248.4 - $316.12 $ 318.638%0
Yacktman Fund 2017-06-30 Sold Out 1.32%$248.4 - $316.12 $ 318.638%0
Donald Yacktman 2017-03-31 Reduce -31.43%0.47%$226.56 - $250.85 $ 318.6332%496,394
Yacktman Fund 2017-03-31 Reduce -36.36%0.68%$226.56 - $250.85 $ 318.6332%350,000
Joel Greenblatt 2017-03-31 Reduce -75.55%0.11%$226.56 - $250.85 $ 318.6332%12,431
George Soros 2017-03-31 Sold Out 0.01%$226.56 - $250.85 $ 318.6332%0
Donald Yacktman 2016-12-31 Reduce -2.04%0.03%$203.77 - $227.45 $ 318.6347%723,901
Joel Greenblatt 2016-12-31 Add 1252.26%0.14%$203.77 - $227.45 $ 318.6347%50,845
George Soros 2016-12-31 New Buy0.01%$203.77 - $227.45 $ 318.6347%900
Donald Yacktman 2016-09-30 Reduce -8.35%0.13%$213.02 - $239 $ 318.6342%738,964
Yacktman Fund 2016-09-30 Reduce -15.38%0.33%$213.02 - $239 $ 318.6342%550,000
Joel Greenblatt 2016-09-30 Reduce -32.64%0.01%$213.02 - $239 $ 318.6342%3,760
Tom Gayner 2016-09-30 Sold Out 0.06%$213.02 - $239 $ 318.6342%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:MTD, NAS:ILMN, NYSE:WAT, NAS:XRAY, NYSE:COO, NYSE:BAX, NYSE:RMD, NAS:HOLX, NYSE:WST, NYSE:HRC, NAS:ICUI, NYSE:CMD, NAS:PODD, NYSE:HAE, NYSE:HYH, NAS:MMSI, NYSE:BDX, NAS:NXTM, NAS:OSUR, NAS:ATRI » details
Traded in other countries:BR6.Germany,
Headquarter Location:USA
C.R. Bard Inc manufactures, distributes and sells medical, surgical, diagnostic and patient care devices. The company sells its products to hospitals, individual healthcare professionals, and extended care facilities.

C.R. Bard designs, manufactures, and markets a wide range of medical, diagnostic, and surgical devices that are primarily intended for one-time use. The firm enjoys a sizable footprint in key therapeutic areas, including urology, oncology, peripheral vascular solutions, soft tissue surgery, and breast biopsy and reconstruction. Sales to foreign countries account for approximately one third of total revenue.

Guru Investment Theses on C.R. Bard Inc

Mario Gabelli Comments on C.R. Bard Inc. - Aug 15, 2017

C.R. Bard Inc.(3% of net asset as of June 30 ,2017)(BCR–$316.11–NYSE)(NYSE:BCR) is a New Providence, New Jersey based medical equipment company that distributes diagnostic and patient care products. BCR agreed to be acquired by Becton Dickinson and Co. (BDX) on April 23, 2017 for $222.93 cash + 0.5077 BDX per share stock. The transaction requires regulatory and shareholder approvals and is expected to close in the fall of 2017.



From Mario Gabelli (Trades, Portfolio)'s second quarter 2017 Gabelli ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Donald Yacktman Comments on C.R. Bard - Nov 05, 2015

C.R. Bard (NYSE:BCR) was a solid performer in the third quarter. As a result, we reduced the Fund’s position size in Bard.

From Donald Yacktman (Trades, Portfolio)'s third quarter 2015 commentary.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about C.R. Bard Inc

Leucadia National Buys Altaba, Huntsman, C.R. Bard The firm's top 8 2nd-quarter buys
Leucadia National (Trades, Portfolio) bought shares of the following stocks during the second quarter: Read more...
Mario Gabelli Comments on C.R. Bard Inc. Guru stock highlight
C.R. Bard Inc.(3% of net asset as of June 30 ,2017)(BCR–$316.11–NYSE)(NYSE:BCR) is a New Providence, New Jersey based medical equipment company that distributes diagnostic and patient care products. BCR agreed to be acquired by Becton Dickinson and Co. (BDX) on April 23, 2017 for $222.93 cash + 0.5077 BDX per share stock. The transaction requires regulatory and shareholder approvals and is expected to close in the fall of 2017. Read more...
Yacktman Asset Management's Largest 2nd-Quarter Trades The firm releases quarterly portfolio
Yacktman Asset Management (TradesPortfolio), which is managed by Stephen Yacktman and Jason Subotky, made the following trades during the second quarter. Read more...
Bard Shareholders Approve Proposed Merger With Becton, Dickinson
Yacktman Funds Bet on IT Companies The funds invested in Cognizant Technology, Infosys in 2nd quarter
The Yacktman Focused Fund (Trades, Portfolio) and the Yacktman Fund (Trades, Portfolio) initiated holdings in Cognizant Technology Solutions Corp. (NASDAQ:CTSH) and Infosys Ltd. (NYSE:INFY) during the second quarter. Read more...
BD and Bard Receive Second Requests from FTC under HSR Act
Lifshitz & Miller LLP Announces Investigation of C. R. Bard, Inc., HCSB Financial Corp., Home Capital Group Inc., Paragon Commercial Corporation, PCM, Inc., Pingtan Marine Enterprise Ltd. and United States Steel Corporation
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of C. R. Bard, Inc. to Becton, Dickinson and Company for $317 Per Share is Fair to Shareholders - BCR
WeissLaw LLP: The C. R. Bard, Inc. and Becton, Dickson and Company Merger May Not Be in the Best Interests of BCR Unitholders
C.R. BARD INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of C.R. Bard, Inc.

Ratios

vs
industry
vs
history
PE Ratio 41.87
BCR's PE Ratio is ranked lower than
72% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. BCR: 41.87 )
Ranked among companies with meaningful PE Ratio only.
BCR' s PE Ratio Range Over the Past 10 Years
Min: 14.25  Med: 25.17 Max: 154.75
Current: 41.87
14.25
154.75
Forward PE Ratio 25.32
BCR's Forward PE Ratio is ranked higher than
53% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.25 vs. BCR: 25.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 41.87
BCR's PE Ratio without NRI is ranked lower than
72% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. BCR: 41.87 )
Ranked among companies with meaningful PE Ratio without NRI only.
BCR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.25  Med: 24.74 Max: 154.75
Current: 41.87
14.25
154.75
Price-to-Owner-Earnings 94.52
BCR's Price-to-Owner-Earnings is ranked lower than
88% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.16 vs. BCR: 94.52 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BCR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.25  Med: 25.02 Max: 434.61
Current: 94.52
12.25
434.61
PB Ratio 12.47
BCR's PB Ratio is ranked lower than
96% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. BCR: 12.47 )
Ranked among companies with meaningful PB Ratio only.
BCR' s PB Ratio Range Over the Past 10 Years
Min: 3.22  Med: 4.86 Max: 13.37
Current: 12.47
3.22
13.37
PS Ratio 6.24
BCR's PS Ratio is ranked lower than
72% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. BCR: 6.24 )
Ranked among companies with meaningful PS Ratio only.
BCR' s PS Ratio Range Over the Past 10 Years
Min: 2.55  Med: 3.64 Max: 6.35
Current: 6.24
2.55
6.35
Price-to-Free-Cash-Flow 41.21
BCR's Price-to-Free-Cash-Flow is ranked lower than
73% of the 70 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.92 vs. BCR: 41.21 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BCR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.99  Med: 17.61 Max: 49.94
Current: 41.21
9.99
49.94
Price-to-Operating-Cash-Flow 33.79
BCR's Price-to-Operating-Cash-Flow is ranked lower than
77% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. BCR: 33.79 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BCR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.99  Med: 14.99 Max: 40.5
Current: 33.79
8.99
40.5
EV-to-EBIT 32.06
BCR's EV-to-EBIT is ranked lower than
69% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. BCR: 32.06 )
Ranked among companies with meaningful EV-to-EBIT only.
BCR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 16.05 Max: 49.4
Current: 32.06
8
49.4
EV-to-EBITDA 25.02
BCR's EV-to-EBITDA is ranked lower than
71% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. BCR: 25.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
BCR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 13.4 Max: 31.5
Current: 25.02
7.2
31.5
EV-to-Revenue 6.23
BCR's EV-to-Revenue is ranked lower than
72% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.43 vs. BCR: 6.23 )
Ranked among companies with meaningful EV-to-Revenue only.
BCR' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.6  Med: 3.7 Max: 6.5
Current: 6.23
2.6
6.5
PEG Ratio 18.22
BCR's PEG Ratio is ranked lower than
98% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. BCR: 18.22 )
Ranked among companies with meaningful PEG Ratio only.
BCR' s PEG Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.67 Max: 40.4
Current: 18.22
0.92
40.4
Shiller PE Ratio 58.23
BCR's Shiller PE Ratio is ranked lower than
57% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. BCR: 58.23 )
Ranked among companies with meaningful Shiller PE Ratio only.
BCR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.41  Med: 31.72 Max: 59.22
Current: 58.23
23.41
59.22
Current Ratio 1.58
BCR's Current Ratio is ranked lower than
77% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. BCR: 1.58 )
Ranked among companies with meaningful Current Ratio only.
BCR' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.21 Max: 5.88
Current: 1.58
1.14
5.88
Quick Ratio 1.24
BCR's Quick Ratio is ranked lower than
71% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. BCR: 1.24 )
Ranked among companies with meaningful Quick Ratio only.
BCR' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.65 Max: 4.72
Current: 1.24
0.62
4.72
Days Inventory 126.49
BCR's Days Inventory is ranked higher than
53% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. BCR: 126.49 )
Ranked among companies with meaningful Days Inventory only.
BCR' s Days Inventory Range Over the Past 10 Years
Min: 99.01  Med: 105.62 Max: 126.49
Current: 126.49
99.01
126.49
Days Sales Outstanding 45.46
BCR's Days Sales Outstanding is ranked higher than
77% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. BCR: 45.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.46  Med: 59 Max: 63.66
Current: 45.46
45.46
63.66
Days Payable 24.03
BCR's Days Payable is ranked lower than
86% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. BCR: 24.03 )
Ranked among companies with meaningful Days Payable only.
BCR' s Days Payable Range Over the Past 10 Years
Min: 18.23  Med: 20.88 Max: 28.74
Current: 24.03
18.23
28.74

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.33
BCR's Dividend Yield % is ranked lower than
91% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. BCR: 0.33 )
Ranked among companies with meaningful Dividend Yield % only.
BCR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.32  Med: 0.67 Max: 0.9
Current: 0.33
0.32
0.9
Dividend Payout Ratio 0.14
BCR's Dividend Payout Ratio is ranked higher than
84% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BCR: 0.14 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BCR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.15 Max: 0.52
Current: 0.14
0.1
0.52
3-Year Dividend Growth Rate 6.80
BCR's 3-Year Dividend Growth Rate is ranked lower than
60% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. BCR: 6.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BCR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 24.1
Current: 6.8
3.2
24.1
Forward Dividend Yield % 0.33
BCR's Forward Dividend Yield % is ranked lower than
92% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. BCR: 0.33 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.44
BCR's 5-Year Yield-on-Cost % is ranked lower than
86% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BCR: 0.44 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BCR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.43  Med: 0.9 Max: 1.2
Current: 0.44
0.43
1.2
3-Year Average Share Buyback Ratio 2.00
BCR's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. BCR: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3  Med: 1.6 Max: 5.3
Current: 2
-3
5.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.83
BCR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. BCR: 2.83 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BCR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.89  Med: 1.58 Max: 2.87
Current: 2.83
0.89
2.87
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.91
BCR's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
86% of the 22 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. BCR: 3.91 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BCR' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.66  Med: 1.3 Max: 13.33
Current: 3.91
0.66
13.33
Price-to-Median-PS-Value 1.71
BCR's Price-to-Median-PS-Value is ranked lower than
81% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. BCR: 1.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.71 Max: 1.71
Current: 1.71
0.26
1.71
Earnings Yield (Greenblatt) % 3.12
BCR's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. BCR: 3.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 6.2 Max: 12.5
Current: 3.12
2
12.5
Forward Rate of Return (Yacktman) % 3.83
BCR's Forward Rate of Return (Yacktman) % is ranked lower than
68% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. BCR: 3.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BCR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.8  Med: 17.3 Max: 22.5
Current: 3.83
3.8
22.5

More Statistics

Revenue (TTM) (Mil) $3,827.50
EPS (TTM) $ 7.61
Beta0.43
Short Percentage of Float1.28%
52-Week Range $203.63 - 324.58
Shares Outstanding (Mil)72.67

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 3,935 4,170 4,264
EPS ($) 11.61 12.57 14.26 15.09
EPS without NRI ($) 11.61 12.57 14.26 15.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.19%
Dividends per Share ($) 0.99 0.99
» More Articles for BCR

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on C.R. Bard Inc. Aug 15 2017 
Leucadia National Buys Altaba, Huntsman, C.R. Bard Aug 15 2017 
The Gabelli ABC Fund Merger and Arbitrage 2nd Quarter Shareholder Commentary Aug 15 2017 
Yacktman Asset Management's Largest 2nd-Quarter Trades Aug 10 2017 
Bard Shareholders Approve Proposed Merger With Becton, Dickinson Aug 08 2017 
5 Companies Hit 52-Week Highs Aug 08 2017 
Yacktman Funds Bet on IT Companies Jul 19 2017 
BD and Bard Receive Second Requests from FTC under HSR Act Jun 09 2017 
Lifshitz & Miller LLP Announces Investigation of C. R. Bard, Inc., HCSB Financial Corp., Home Capita May 15 2017 
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of C. R Apr 27 2017 

More From Other Websites
C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US :... Sep 18 2017
BD Stock Fell 2.7% on September 13: Should Investors Worry? Sep 15 2017
Becton, Dickinson's (BCR) C.R. Bard Buyout Plans Bode Well Sep 12 2017
C.R. Bard, Inc. (New Jersey) – Value Analysis (NYSE:BCR) : September 6, 2017 Sep 05 2017
C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bullish Manner : BCR-US :... Sep 01 2017
C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval Aug 29 2017
Becton Dickinson’s Bard Acquisition: On Track, Gaining Momentum Aug 28 2017
C. R. Bard Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Balloon as the First and... Aug 28 2017
C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : July 24th, 2017 (record date) : By the... Aug 25 2017
C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US :... Aug 21 2017
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : August 15, 2017 Aug 15 2017
C.R. Bard Shareholders Approve Merger With Becton, Dickinson Aug 09 2017
Bard Shareholders Approve Proposed Merger With Becton, Dickinson Aug 08 2017
C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Aug 01 2017
Featured Company News - Haemonetics Announces FDA Clearance for its NexSys PCS; Set to Reduce Cost... Jul 31 2017
C.R. Bard (BCR) Beats Earnings & Revenue Estimates in Q2 Jul 28 2017
C.R. Bard tops Street 2Q forecasts Jul 27 2017
Bard Announces Second Quarter Results Jul 27 2017
Is a Surprise in Store for CR Bard (BCR) in Q2 Earnings? Jul 20 2017
Becton, Dickinson (BDX) Poised on C.R. Bard Acquisition Jul 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}